Dako and Cytomation join operations
This article was originally published in Clinica
Executive Summary
Danish diagnostic company Dako is to combine operations with Cytomation, of Fort Collins, Colorado. The deal brings together Cytomation's bioinstrumentation and software with Dako's biotech and diagnostic experience. The unit will be headed by Copenhagen-based Dako's president and CEO, Jes Estergaard, while Nigel Ferrey, Cytomation's president and CEO, will be responsible for US operations. He will also join the corporate management group.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.